LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Y39983 | 10 | uM | LJP6 | 3 | P01 | 72 | hr | 1235 | 373 | 4583 | 0.0814 | -0.4693 |
MDA-MB-231 | Nintedanib | 0.04 | uM | LJP6 | 1 | H06 | 72 | hr | 1235 | 4957 | 4355 | 1.1380 | 1.1474 |
MDA-MB-231 | Nintedanib | 0.04 | uM | LJP6 | 2 | H06 | 72 | hr | 1235 | 4735 | 4277 | 1.1070 | 1.1168 |
MDA-MB-231 | Nintedanib | 0.04 | uM | LJP6 | 3 | H06 | 72 | hr | 1235 | 4843 | 4583 | 1.0566 | 1.0591 |
MDA-MB-231 | Nintedanib | 0.12 | uM | LJP6 | 1 | H05 | 72 | hr | 1235 | 4813 | 4355 | 1.1049 | 1.1129 |
MDA-MB-231 | Nintedanib | 0.12 | uM | LJP6 | 2 | H05 | 72 | hr | 1235 | 4675 | 4277 | 1.0930 | 1.1018 |
MDA-MB-231 | Nintedanib | 0.12 | uM | LJP6 | 3 | H05 | 72 | hr | 1235 | 4488 | 4583 | 0.9792 | 0.9779 |
MDA-MB-231 | Nintedanib | 0.37 | uM | LJP6 | 1 | H04 | 72 | hr | 1235 | 4482 | 4355 | 1.0289 | 1.0316 |
MDA-MB-231 | Nintedanib | 0.37 | uM | LJP6 | 2 | H04 | 72 | hr | 1235 | 4134 | 4277 | 0.9665 | 0.9623 |
MDA-MB-231 | Nintedanib | 0.37 | uM | LJP6 | 3 | H04 | 72 | hr | 1235 | 4617 | 4583 | 1.0073 | 1.0078 |
MDA-MB-231 | Nintedanib | 1.11 | uM | LJP6 | 1 | H03 | 72 | hr | 1235 | 4302 | 4355 | 0.9876 | 0.9863 |
MDA-MB-231 | Nintedanib | 1.11 | uM | LJP6 | 2 | H03 | 72 | hr | 1235 | 4295 | 4277 | 1.0041 | 1.0046 |
MDA-MB-231 | Nintedanib | 1.11 | uM | LJP6 | 3 | H03 | 72 | hr | 1235 | 4250 | 4583 | 0.9273 | 0.9217 |
MDA-MB-231 | Nintedanib | 3.33 | uM | LJP6 | 1 | H02 | 72 | hr | 1235 | 4062 | 4355 | 0.9325 | 0.9246 |
MDA-MB-231 | Nintedanib | 3.33 | uM | LJP6 | 2 | H02 | 72 | hr | 1235 | 4082 | 4277 | 0.9543 | 0.9485 |
MDA-MB-231 | Nintedanib | 3.33 | uM | LJP6 | 3 | H02 | 72 | hr | 1235 | 4093 | 4583 | 0.8930 | 0.8838 |
MDA-MB-231 | Nintedanib | 10 | uM | LJP6 | 1 | H01 | 72 | hr | 1235 | 803 | 4355 | 0.1844 | -0.2112 |
MDA-MB-231 | Nintedanib | 10 | uM | LJP6 | 2 | H01 | 72 | hr | 1235 | 945 | 4277 | 0.2209 | -0.1392 |
MDA-MB-231 | Nintedanib | 10 | uM | LJP6 | 3 | H01 | 72 | hr | 1235 | 1551 | 4583 | 0.3384 | 0.1276 |
MDA-MB-231 | Foretinib | 0.04 | uM | LJP5 | 1 | H12 | 72 | hr | 1235 | 4050 | 4474 | 0.9051 | 0.8954 |
MDA-MB-231 | Foretinib | 0.04 | uM | LJP5 | 2 | H12 | 72 | hr | 1235 | 4231 | 4578 | 0.9241 | 0.9182 |
MDA-MB-231 | Foretinib | 0.04 | uM | LJP5 | 3 | H12 | 72 | hr | 1235 | 4518 | 4929 | 0.9166 | 0.9146 |
MDA-MB-231 | Foretinib | 0.12 | uM | LJP5 | 1 | H11 | 72 | hr | 1235 | 2735 | 4474 | 0.6112 | 0.5341 |
MDA-MB-231 | Foretinib | 0.12 | uM | LJP5 | 2 | H11 | 72 | hr | 1235 | 3249 | 4578 | 0.7096 | 0.6679 |
MDA-MB-231 | Foretinib | 0.12 | uM | LJP5 | 3 | H11 | 72 | hr | 1235 | 3261 | 4929 | 0.6616 | 0.6260 |